|Bid||0.00 x 3100|
|Ask||0.00 x 1800|
|Day's Range||2.60 - 2.75|
|52 Week Range||1.70 - 3.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.60|
Raleigh’s BioDelivery Sciences International has filed a lawsuit suit against a New Jersey firm in an attempt to defend its flagship product.
RALEIGH, N.C., Sept. 13, 2018-- BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced ...
RALEIGH, N.C., Sept. 10, 2018-- BioDelivery Sciences International, Inc., a leading commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that ...
In its annual analysis of highest-paid CEOs of Triangle-based publicly traded companies, Triangle Business Journal parses the data in a myriad of ways that peers beyond the numbers.
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aurora ...
RALEIGH, N.C., Aug. 21, 2018-- BioDelivery Sciences International, Inc.,, a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm ...
RALEIGH, N.C., Aug. 15, 2018-- BioDelivery Sciences International, Inc., a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain today announced that a leading ...
Earnings season is in full swing, and companies are busy reporting their performance for the second quarter of the fiscal year. The same is true for Research Triangle Park’s biotech companies, BioDelivery Sciences (Nasdaq: BDSI), TransEnterix (Amex: TRXC) and Dova Pharmaceuticals (Nasdaq: DOVA) all announced their financial results during after-market hours in recent days.
BioDelivery (BDSI) delivered earnings and revenue surprises of 15.79% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Raleigh, North Carolina-based company said it had a loss of 16 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
BELBUCA ® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter. Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of $200 ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at ...
Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.
EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Peter Greenleaf to the EyeGate Board.
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
BioDelivery Sciences International, Inc. (BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has appointed Thomas B. Smith, MD, FAAFP, as Chief Medical Officer and member of the Company’s Executive Leadership Team. Dr. Smith brings nearly thirty years of medical experience and expertise in the field of pain management to BDSI. His extensive and wide-ranging roles include having been Chief Medical Officer at various leading pain companies, head of medical affairs at top tier pharma and CRO companies, as well as running his own private practice. Dr. Smith is a highly published scientific author and has delivered more than 150 presentations in his field of expertise.
RALEIGH, N.C., July 24, 2018-- BioDelivery Sciences International, Inc. today announced that it will report its second quarter 2018 financial results after the close of the U.S. Financial markets on Thursday, ...
Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).
Raleigh’s BioDelivery Sciences International has closed its $50 million equity financing – led by New York-based global equity manager Broadfin Capital – banking net proceeds of $48.9 million.